Reportedly, four new business units will be created namely Primary Care, Multiple Sclerosis, Psychiatry/Neuroscience and respiratory/Transplant/Infectious Disease. The changes will be implemented from May 1 and impact approximately
The goal of the collaboration is to discover, develop, and deliver novel disease-altering therapies in oncology based on the transformational science of Agios’ innovative cancer metabolism research platform.
BioGenes said that the results confirmed the observation of several contract manufacturers that generic HCP assays are only of limited use for detection of HCPs during manufacturing processes.
Reportedly, MDV3100 demonstrated anti-tumor activity in patients with late-stage prostate cancer as evaluated by reductions in prostate specific antigen (PSA) levels, radiographic findings and circulating tumor cell (CTC)
Granisetron is expected to be made available in 0.1mg per ml and 1.0mg per ml single-dose vials, and 4.0mg per 4ml multi-dose vials. Sagent expects to begin marketing
At its initiation, the Phase 2 single blind study in chronic kidney disease patients called for the comparison of two different Heplisav regimens, a single-dose vaccine and a
TD-1211 is a potent, multivalent inhibitor of the mu opioid receptor designed to alleviate gastrointestinal side effects of opioid analgesic therapy without affecting analgesia. TD-1211 has been administered
OrbusNeich Medical noted that it has identified unlicensed use by Boston Scientific of certain technologies protected under US Patent No 7,682,384 B2. As the owner by assignment of
These data indicate that, if clinically validated, VGX-100 has the potential to be a useful new treatment for some types of cancer. VGX-100 is a fully human monoclonal
Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology to administer drugs through
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.